SC
VOR icon

Shay Capital’s Vor Biopharma VOR Stock Holding History

Shay Capital’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-53,800
Closed -$2.62M – 611
2025
Q3 		$2.62M Buy
+53,800
New +$2.16M 0.23% 90

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Shay Capital's VOR Position: Q2 2026 in Review

Shay Capital opened a new position in Vor Biopharma (VOR) in Q2 2026: 13,695 shares worth $252K. The stake represents 0.02% of the portfolio and ranks #376 among its holdings. This is a return to the name: Shay Capital previously reported a position in VOR as recently as Q4 2025.

Shay Capital first reported a position in VOR in Q4 2025 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

  • Shay Capital held 13,695 shares of Vor Biopharma worth $252K as of Q2 2026.
  • Vor Biopharma was a new Shay Capital position in Q2 2026.
  • Vor Biopharma made up 0.02% of Shay Capital's portfolio in Q2 2026, its #376 holding.
  • Shay Capital first reported a position in Vor Biopharma in Q4 2025 and has held it in 2 quarters since.
  • 102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Shay Capital's 13F filing for Q2 2026, filed 14 Aug 2026.